Five-year survival and prognostic factors of cervical cancer (stages I-IV) in Rwanda: a population-based analysis, 2017-2021.
Ange Iradukunda I, Gbadamosi Mojeed Akorede MA
Cervical cancer remains a leading cause of cancer-related mortality among women in low- and middle-income countries. This study assessed five-year survival and prognostic factors among patients diagnosed with cervical cancer in Rwanda. We conducted a population-based retrospective cohort study using data from the Rwanda National Cancer Registry, including patients diagnosed with cervical cancer (Stages I-IV) between 2017 and 2021. Survival probabilities were estimated using the Kaplan-Meier method, and prognostic factors were identified using Cox proportional hazards models. A total of 1,075 patients were included. The mean age at diagnosis was 54.1 years (SD 12.7). FIGO stage distribution at diagnosis was as follows: Stage I (9.0%), Stage II (18.7%), Stage III (32.0%), Stage IV (10.5%), and unknown stage (29.8%). During follow-up, 20.0% of patients died, while 77.7% were censored. An advanced stage at diagnosis was significantly associated with increased mortality (Stage IV vs. Stage I: aHR = 3.84, 95% CI: 1.98-7.45; p < 0.001). In sensitivity analyses, including a worst-case scenario in which the missing stage was classified as Stage IV, the association between advanced stage and mortality remained robust (Stage IV vs. Stage I: aHR = 2.43, 95% CI: 1.26-4.70; p = 0.008). Survival among cervical cancer patients in Rwanda remains strongly associated with stage at diagnosis. The high proportion of advanced-stage disease and missing stage data underscores the need for improved early detection, data completeness, and follow-up systems.